Late‑breaker data from the Majestec‑3 trial presented at ASH showed the combination of teclistamab (Tecvayli) and daratumumab delivered a dramatic progression‑free survival (PFS) benefit in relapsed multiple myeloma. Investigators reported an 83.4% three‑year PFS rate for the combo versus 29.7% with standard care, with presenters calling the effect the largest PFS treatment advantage seen to date. Researchers highlighted a plateau in both PFS and overall survival curves, suggesting potential for a functional cure in a subset of patients. The regimen leverages teclistamab’s T‑cell redirection and daratumumab’s microenvironment priming to amplify anti‑tumor activity. The results will intensify competition among bispecific and cell therapy approaches in myeloma, influence sequencing decisions, and shape payer conversations about high‑cost combination regimens that may deliver durable disease control.